Arrayfunction : It will be interesting to see what the ultimate market share of the drug will be. Did a quick read through the FDA label and compared it to Zofran's (the current "gold standard" as it were) label. Focinvez has some novel potential given it targets different brain receptors than Zofran and previous chemo anti-emetics.
That could help relieve some issues with drug-drug interactions current anti-emetics have (primarily serotonergic effects like SSRIs, serotonin modulators, etc). But it also means Focinvez has its own drug-drug interaction problems (most notably benzodiazepines and blood thinners).
I am not sure how often either issue would arise since I am not a doctor and haven't gone through chemo to know how often those other drug classes are prescribed together. So this may ultimately not have much of a financial impact if only a very small subset of chemo patients would benefit enough from adopting Focinvez to warrant the monumental increase in price compared to others on the market.